Efficacy of a low dose‐range of fluvastatin (XU 62‐320) in the treatment of primary hypercholesterolaemia. A dose‐response study in 431 patients. The French‐Dutch Fluvastatin Study Group.
Data up to Jan 2025
Total Citations Per Year
Abstract
References (12)
HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.
1989 • 336 citations
Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers
1992 • 170 citations
Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay.
1987 • 112 citations
Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor
1988 • 109 citations
Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool.
1980 • 75 citations
A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB.
1989 • 72 citations
Atherosclerosis Reviews
1984 • 56 citations
I. Use of a dietary monitoring tool Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT)
1980 • 51 citations
Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical Trials
1992 • 49 citations
A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia
1991 • 39 citations
Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay.
1985 • 35 citations
Quantification of human apolipoprotein E in plasma and lipoprotein subfractions by a non-competitive enzyme immunoassay
1987 • 25 citations